Cempra Inc. (NASDAQ:CEMP) fell 4.5% during trading on Wednesday . The company traded as low as $21.77 and last traded at $21.83, with a volume of 500,449 shares changing hands. The stock had previously closed at $22.85.

A number of research firms have commented on CEMP. Zacks Investment Research downgraded Cempra from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Needham & Company LLC reissued a “buy” rating and issued a $48.00 target price on shares of Cempra in a report on Wednesday, August 3rd. Cowen and Company reissued a “buy” rating on shares of Cempra in a report on Tuesday, August 2nd. Robert W. Baird restated an “outperform” rating and issued a $33.00 price target on shares of Cempra in a research report on Tuesday, August 2nd. Finally, Jefferies Group dropped their price target on Cempra from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, August 2nd. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Cempra currently has a consensus rating of “Buy” and a consensus target price of $35.17.

The company’s market capitalization is $1.10 billion. The company has a 50 day moving average price of $20.38 and a 200-day moving average price of $18.11.

Cempra (NASDAQ:CEMP) last announced its quarterly earnings results on Monday, August 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.16. The business had revenue of $3.42 million for the quarter, compared to analyst estimates of $3.89 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.57) EPS. On average, equities analysts expect that Cempra Inc. will post ($2.63) earnings per share for the current year.

An institutional investor recently raised its position in Cempra stock. Wells Fargo & Company MN raised its position in Cempra Inc. (NASDAQ:CEMP) by 14.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 307,113 shares of the company’s stock after buying an additional 38,204 shares during the period. Wells Fargo & Company MN owned about 0.70% of Cempra worth $9,561,000 at the end of the most recent quarter.

Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.